Innate Pharma SA
PAR:IPH

Watchlist Manager
Innate Pharma SA Logo
Innate Pharma SA
PAR:IPH
Watchlist
Price: 2 EUR 3.95%
Market Cap: 161.9m EUR
Have any thoughts about
Innate Pharma SA?
Write Note

Wall Street
Price Targets

IPH Price Targets Summary
Innate Pharma SA

Wall Street analysts forecast IPH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IPH is 5.13 EUR with a low forecast of 2.43 EUR and a high forecast of 8.82 EUR.

Lowest
Price Target
2.43 EUR
22% Upside
Average
Price Target
5.13 EUR
156% Upside
Highest
Price Target
8.82 EUR
341% Upside
Innate Pharma SA Competitors:
Price Targets
TNGX
Tango Therapeutics Inc
278% Upside
BVXP
Bioventix PLC
58% Upside
IMTX
Immatics NV
146% Upside
OCC
Orthocell Ltd
56% Downside
ELYM
Eliem Therapeutics Inc
230% Upside
INSM
Insmed Inc
29% Upside
AZT
Arcticzymes Technologies ASA
30% Upside
MIRM
Mirum Pharmaceuticals Inc
54% Upside

Revenue
Forecast

Revenue Estimate
Innate Pharma SA

For the last 8 years the compound annual growth rate for Innate Pharma SA's revenue is 14%. The projected CAGR for the next 4 years is 19%.

14%
Past Growth
19%
Estimated Growth
Estimates Accuracy
-24%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Innate Pharma SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-10%
Average Miss

Net Income
Forecast

Net Income Estimate
Innate Pharma SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
99%
Average Beat

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is IPH's stock price target?
Price Target
5.13 EUR

According to Wall Street analysts, the average 1-year price target for IPH is 5.13 EUR with a low forecast of 2.43 EUR and a high forecast of 8.82 EUR.

What is Innate Pharma SA's Revenue forecast?
Projected CAGR
19%

For the last 8 years the compound annual growth rate for Innate Pharma SA's revenue is 14%. The projected CAGR for the next 4 years is 19%.

Back to Top